Pro-Gly-Pro is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | 95 percent or higher by RP-HPLC | Area percentage of the main peak |
| Identity confirmation | Electrospray ionization mass spectrometry | Observed mass compared with the theoretical value near 751.9 Da |
| Recommended dry storage | -20 °C, desiccated | -80 °C for multi-year archival material |
| Solution handling | Prepare fresh; avoid long storage | Sterile filtration reduces microbial load |
| Common synonyms | TKPRPGP; TP-7 | Sequence code and laboratory designation used interchangeably |
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
=== Aryl cyclooctynes === Fusion of a cyclooctyne to two aryl rings increases the reaction rate, and the cyclooctyne reagents of the Bertozzi group proceeded through a series of fusions that sought to increase the ring strain even further. DIBO (dibenzo cyclooctyne) was developed as a precursor to BARAC (biarylazacyclooctynone), although calculations had predicted that a single fused aryl ring would be optimal. Attempts to make a difluoro benzo cyclooctyne (DIFBO) were unsuccessful due to the instability of the compound. The reason for the instability of DIFBO is that it is so reactive that it spontaneously trimerizes to form two asymmetric products that can be characterized by X-ray crystallography. To stabilize the DIFBO, it is trapped by forming a stable inclusion complex with β-cyclodextrin in aqueous media. This complex, formed with the β-cyclodextrin, can then be stored as a lyophilized powder. To obtain the free DIFBO, the lyophilized powder is dissociated with organic solvents to produce the free DIFBO for in situ kinetic and spectroscopic analysis. Problems with DIFO with in vivo mouse studies illustrate the difficulty of producing bioorthogonal reactions.
==== Campaign on the Min River and final retreat to Xikang (July–October 1933) ==== Liu's defensive line on the west bank of the Min River did not last long, and Liu Xiang's forces crossed it at several points. Morale within the 24th Army collapsed, and desertion was rampant. Liu finally decided to retreat to Mingshan, which guarded the entrance to Ya'an. It was in Ya'an that Liu hoped to reorganize his forces, but he was pursued even here, narrowly escaping with his life after artillery shelled his headquarters. Liu retreated even further into Xikang proper, entering the Ningyuan region. Because Xikang was a desolate country, with few hopes of earning provisions or pay, he voluntarily let many of his officers and soldiers leave the army. Liu later said the loss of most of his army was the "greatest grievance" of his life. It was at this point where Liu Wenhui telegraphed an apology to his nephew and declared his support for Sichuanese unification. He had also gotten his eldest brother to appeal on his behalf. Liu Xiang also relented, recognizing that fully eliminating Liu Wenhui's forces could leave an opening for Deng Xihou and others in Sichuan to gain power. Judging that his uncle was no longer a threat, Liu Xiang ordered his commander Li Hongkun to retreat from Ya'an on 8 October, clearing the way for Liu Wenhui to return to the town on 24 October and ending the Two-Liu War. In the aftermath of the war, Liu Wenhui was left with his remaining possessions in Xikang, having lost the entire Sichuan basin to Liu Xiang.
A clinical trial protocol is a document used to define and manage the trial. It is prepared by a panel of experts. All study investigators are expected to strictly observe the protocol. The protocol describes the scientific rationale, objective(s), design, methodology, statistical considerations and organization of the planned trial. Details of the trial are provided in documents referenced in the protocol, such as an investigator's brochure. The protocol contains a precise study plan to assure safety and health of the trial subjects and to provide an exact template for trial conduct by investigators. This allows data to be combined across all investigators/sites. The protocol also informs the study administrators (often a contract research organization). The format and content of clinical trial protocols sponsored by pharmaceutical, biotechnology or medical device companies in the United States, European Union, or Japan have been standardized to follow Good Clinical Practice guidance issued by the International Conference on Harmonisation (ICH). Regulatory authorities in Canada, China, South Korea, and the UK also follow ICH guidelines. Journals such as Trials, encourage investigators to publish their protocols.
Sources: en.wikipedia.org
== Collagen and accessory proteins == Almost all of the organic (non-mineral) component of bone is dense collagen type I, which forms dense crosslinked ropes that give bone its tensile strength. By mechanisms still unclear, osteoblasts secrete layers of oriented collagen, with the layers parallel to the long axis of the bone alternating with layers at right angles to the long axis of the bone every few micrometers. Defects in collagen type I cause the commonest inherited disorder of bone, called osteogenesis imperfecta. Minor, but important, amounts of small proteins, including osteocalcin and osteopontin, are secreted in bone's organic matrix. Osteocalcin is not expressed at significant concentrations except in bone, and thus osteocalcin is a specific marker for bone matrix synthesis. These proteins link organic and mineral component of bone matrix. The proteins are necessary for maximal matrix strength due to their intermediate localization between mineral and collagen. However, in mice where expression of osteocalcin or osteopontin was eliminated by targeted disruption of the respective genes (knockout mice), accumulation of mineral was not notably affected, indicating that organization of matrix is not significantly related to mineral transport.
=== Natural occurrence === Earth has retained all of the noble gases that were present at its formation except helium. Krypton's concentration in the atmosphere is about 1 ppm. It can be extracted from liquid air by fractional distillation. The amount of krypton in space is uncertain, because measurement is derived from meteoric activity and solar winds. The first measurements suggest an abundance of krypton in space.
After concluding that continued hostilities would risk economic calamity, Donald Trump signed a memorandum of understanding (MOU) on behalf of the United States during a ceremony at the Palace of Versailles on 17 June 2026. The signing followed an earlier, digital signing of the MOU by the foreign ministers of the two principal belligerents. In the MOU, the United States and Iran agreed to suspend hostilities for 60 days and to establish a framework for a permanent peace under which the US would make major financial and political concessions to the Islamic Republic of Iran. The memorandum began to collapse on 7 July 2026, when Iranian forces attacked three commercial vessels in the Strait of Hormuz, including a Qatari LNG tanker, setting it ablaze and damaging other ships. Iranian officials told The New York Times that internal inquiries traced the decision to Hossein Taeb, head of the Basij and former Revolutionary Guards’ intelligence agency chief. The United States responded with airstrikes on Iranian territory within a day of the ship attacks, effectively ending the ceasefire and resuming hostilities between the two countries.
Sources: en.wikipedia.org
Sealed, desiccated storage at -20 °C or colder is the standard recommendation for research-grade material. Vials should reach room temperature before they are opened, which limits condensation. Repeated temperature cycling is discouraged.
A reported purity value reflects the share of the main peak in one chromatographic run and says nothing about identity. Confirming that the expected sequence is present requires a separate measurement such as mass spectrometry. Purity and identity are distinct questions.
A mass spectrum reports the molecular masses present in a sample and shows whether they match the value expected for selank, near 751.9 Da. It also flags common artifacts such as truncation or adduct formation. It does not establish correct stereochemistry or complete sequence order on its own.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.